clinical trial · NCT07268612
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
Emergent BioSolutions·—·not yet recruiting·n = 250
AnthraxCYFENDUS
brief summary
The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent inhalational anthrax and/or anthrax meningitis.
started
Nov 1, 2035
primary completion
Nov 1, 2036
completion
Nov 1, 2037
last updated
Dec 8, 2025
official title
A Phase 4 Retrospective Observational Study of CYFENDUS™ Anthrax Vaccine Among Individuals Who Received Post-Exposure Prophylaxis Vaccination During a Bacillus Anthracis Mass Exposure Event
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol